Speak directly to the analyst to clarify any post sales queries you may have.
Cancer/tumor profiling is a laboratory method that analyzes specific proteins, genes, and other molecules in a tumor to provide information about any genetic or molecular changes, such as gene mutations. Tumor profiling is the technology that oncologists widely use to determine if the pathways of a patient’s tumor match up with available targeted treatments. Accelerated use of biomarkers in the treatment of cancer patients and increasing preference for customized cancer treatments coupled with government and international organization's efforts to develop cancer diagnosis methods support the widespread use of cancer/tumor profiling technologies. On the other hand, high capital investment in cancer/tumor profiling tools and services and low biomarker discovery-to-approval ratio hinders market development. However, the spread of next-generation sequencing, tumor profiling improvements, and point-of-care cancer detection technology expansion is expected to surge their use in the coming years.
Regional Insights
Cancer/tumor profiling market landscape in North America, the EU, GCC, and developed countries across the Asia-Pacific region are highly advanced due to prominent market players and well-established regulatory frameworks and initiatives launched by the governments to reduce cancer burden while improving patient care. Cancer profiling is gradually gaining prominence in developing economies worldwide as investments in cancer diagnostics continue to rise. According to the American Cancer Society, approximately 1.9 million new cancer cases are anticipated to be diagnosed in the United States in 2023, bolstering the need for cancer profiling. Northern and Western European countries observe considerably high use and availability of biomarker testing procedures, re?ecting their higher investment in healthcare. Market players across countries are collaborating with technology providers in the United States and European countries and each other to contribute to deploying the advancement in cancer diagnosis, profiling, and treatment procedures. Furthermore, the ongoing campaigns and cancer awareness programs have highlighted the need for cancer/tumor profiling in Asian countries.FPNV Positioning Matrix
The FPNV Positioning Matrix is pivotal in evaluating the Cancer/Tumor Profiling Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).Market Share Analysis
The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Cancer/Tumor Profiling Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.Key Company Profiles
The report delves into recent significant developments in the Cancer/Tumor Profiling Market, highlighting leading vendors and their innovative profiles. These include 4basecare Onco Solutions Private Limited, ACT Genomics Co., Ltd. by Prenetics Global Limited, Agendia, Inc., Agilent Technologies, Inc., BostonGene Corporation, Caris Life Sciences, Exact Sciences Corporation, F. Hoffmann-La Roche Ltd., GENINUS Inc., Genomic Life, GenScript Biotech Corporation, Guardant Health, Inc., Hologic, Inc., HTG Molecular Diagnostics, Inc., Illumina, Inc., IMBdx, Inc., Laboratory Corporation of America Holdings, Lucence Health, Inc., Merck KGaA, NanoString Technologies, Inc., Neogenomics, Inc., Nonacus Limited, OncoDNA S.A., Oncompass Medicine Hungary Kft., Paragon Genomics, Inc., Personalis, Inc., Perthera, Inc., Predictive Oncology Inc., Strand Life Sciences, Sysmex Corporation, Takara Bio Inc., Tempus Labs Inc., and Thermo Fisher Scientific Inc.Market Segmentation & Coverage
This research report categorizes the Cancer/Tumor Profiling Market to forecast the revenues and analyze trends in each of the following sub-markets:- Technology
- Immunoassays
- In-Situ Hybridization
- Mass Spectrometry
- Microarrays
- Next-Generation Sequencing
- Polymerase Chain Reaction
- Biomarker Type
- Genomic Biomarker
- Protein Biomarker
- Cancer Type
- Breast Cancer
- Colorectal Cancer
- Lung Cancer
- Melanoma Cancer
- Prostate Cancer
- Application
- Biomarker Discovery
- Clinical Application
- Diagnostics
- Personalized Medicine
- Prognostics
- Research
- Screening
- Treatment & Monitoring
- Region
- Americas
- Argentina
- Brazil
- Canada
- Mexico
- United States
- California
- Florida
- Illinois
- New York
- Ohio
- Pennsylvania
- Texas
- Asia-Pacific
- Australia
- China
- India
- Indonesia
- Japan
- Malaysia
- Philippines
- Singapore
- South Korea
- Taiwan
- Thailand
- Vietnam
- Europe, Middle East & Africa
- Denmark
- Egypt
- Finland
- France
- Germany
- Israel
- Italy
- Netherlands
- Nigeria
- Norway
- Poland
- Qatar
- Russia
- Saudi Arabia
- South Africa
- Spain
- Sweden
- Switzerland
- Turkey
- United Arab Emirates
- United Kingdom
- Americas
The report offers valuable insights on the following aspects
- Market Penetration: It presents comprehensive information on the market provided by key players.
- Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.
- Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.
- Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.
- Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.
The report addresses key questions such as
- What is the market size and forecast of the Cancer/Tumor Profiling Market?
- Which products, segments, applications, and areas should one consider investing in over the forecast period in the Cancer/Tumor Profiling Market?
- What are the technology trends and regulatory frameworks in the Cancer/Tumor Profiling Market?
- What is the market share of the leading vendors in the Cancer/Tumor Profiling Market?
- Which modes and strategic moves are suitable for entering the Cancer/Tumor Profiling Market?
Please note: For this report, the purchase of an Enterprise license allows up to ten worldwide users of an organization access to the report
Please note: This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.
With the purchase of this report at the Multi-user License or greater level, you will have access to one hour with an expert analyst who will help you link key findings in the report to the business issues you're addressing. This will need to be used within three months of purchase.
This report also includes a complimentary Excel file with data from the report for purchasers at the Site License or greater level.
Table of Contents
Companies Mentioned
- 4basecare Onco Solutions Private Limited
- ACT Genomics Co., Ltd. by Prenetics Global Limited
- Agendia, Inc.
- Agilent Technologies, Inc.
- BostonGene Corporation
- Caris Life Sciences
- Exact Sciences Corporation
- F. Hoffmann-La Roche Ltd.
- GENINUS Inc.
- Genomic Life
- GenScript Biotech Corporation
- Guardant Health, Inc.
- Hologic, Inc.
- HTG Molecular Diagnostics, Inc.
- Illumina, Inc.
- IMBdx, Inc.
- Laboratory Corporation of America Holdings
- Lucence Health, Inc.
- Merck KGaA
- NanoString Technologies, Inc.
- Neogenomics, Inc.
- Nonacus Limited
- OncoDNA S.A.
- Oncompass Medicine Hungary Kft.
- Paragon Genomics, Inc.
- Personalis, Inc.
- Perthera, Inc.
- Predictive Oncology Inc.
- Strand Life Sciences
- Sysmex Corporation
- Takara Bio Inc.
- Tempus Labs Inc.
- Thermo Fisher Scientific Inc.
Methodology
LOADING...
Table Information
Report Attribute | Details |
---|---|
No. of Pages | 184 |
Published | March 2024 |
Forecast Period | 2023 - 2030 |
Estimated Market Value ( USD | $ 10.79 Billion |
Forecasted Market Value ( USD | $ 35.94 Billion |
Compound Annual Growth Rate | 18.6% |
Regions Covered | Global |
No. of Companies Mentioned | 33 |